Agomab Therapeutics is preparing to begin dosing patients in its phase 2b NOV-ERA study of ontunisertib for fibrostenosing Crohn’s...
Lire la suiteTeva Pharmaceutical Industries has submitted a New Drug Application to the U.S. Food and Drug Administration for ecopipam, an...
Lire la suiteAnocca has treated the first patients with its precision TCR T cell therapy, ANOC 001. NICE has recommended the...
Lire la suiteJohnson & Johnson’s nipocalimab met the primary endpoint in the phase 2 JASMINE study involving adults with moderate-to-severe systemic...
Lire la suiteResolution Therapeutics has welcomed four-year follow-up data from the University of Edinburgh’s MATCH trial into regenerative macrophage therapy for...
Lire la suiteHaemaLogiX opens enrollment for the phase 1 KOALA trial of KMCAR T-cell therapy in relapsed or refractory kappa-restricted multiple...
Lire la suite